EUVIMEDSkopri EUVIMED
Übersichtsarbeit

The role of neurogenic inflammation and CGRP in migraine headache

Luigi F Iannone iD, Edoardo Calussi iD, Nigel W Bunnett iD, Pierangelo Geppetti iD

British Journal of Pharmacology · 2026-11-02

DOI: 10.1111/bph.70715 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2026-11-02. Written by Luigi F Iannone and 3 co-authors. Institution: Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy. 169 references. Funded by: US Department of War, European Research Council, NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The last 40 years have witnessed a thorough change in our understanding of the mechanisms underlying migraine, initiated by the discovery of calcitonin gene‐related peptide (CGRP). A century ago, William Bayliss, Thomas Lewis and other pioneers introduced a visionary neurophysiological mechanism, brought about by peripheral terminals of a specialized subset of primary sensory neurons, which was named ‘neurogenic inflammation’; in both mammal and human skin, action potentials generated by injured nerve terminals of primary sensory neurons can invade collateral fibres via antidromic conduction and release a mediator that ‘produces the flare and enhances sensitivity of other sensory axons responsible for pain’. This mediator, much later identified as CGRP, provides the missing link between these early observations and modern therapeutic targets. Multiple monoclonal antibodies against CGRP or its receptor along with orally available small molecule antagonists of the CGRP receptor have revolutionized the prevention and acute treatment of migraine. The pharmacokinetic features of anti‐CGRP drugs and the paracrine actions of CGRP suggest the proposal that the mechanism underlying migraine headache occurs in a spatially limited microenvironment located outside the blood–brain barrier. According to this hypothesis, the migraine headache milieu comprises CGRP‐containing peripheral sensory nerve endings (C‐fibre nociceptors) and neighbouring cells, including other nerve fibres (Aδ‐fibres), vascular smooth muscle cells and Schwann cells wrapping these nerve fibres.

Subjects

Author keywords

anti‐CGRP drugsnocifensor systempainprimary sensory neuronsvasodilatation

Authors and institutions

  • Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
  • Unit of Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.
  • Department of Molecular Pathobiology, Pain Research Center, College of Dentistry, New York University, New York, New York, USA.
  • Section of Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy.

ORCID profiles: Luigi F Iannone, Edoardo Calussi, Nigel W Bunnett, Pierangelo Geppetti

Funding

  • US Department of War
  • European Research Council
  • NIH HHS
  • U.S. Department of War
  • National Institutes of Health

Cite

APA

Iannone, L. F., Calussi, E., Bunnett, N. W., & Geppetti, P. (2026). The role of neurogenic inflammation and CGRP in migraine headache. British Journal of Pharmacology. https://doi.org/10.1111/bph.70715

Vancouver

Iannone LF, Calussi E, Bunnett NW, Geppetti P. The role of neurogenic inflammation and CGRP in migraine headache. British Journal of Pharmacology. 2026. doi:10.1111/bph.70715

BibTeX
@article{Iannone2026,
  author = {Iannone, Luigi F and Calussi, Edoardo and Bunnett, Nigel W and Geppetti, Pierangelo},
  title = {The role of neurogenic inflammation and CGRP in migraine headache},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70715}
}
Start for free →